Clariane SE (CHIX:CLARIP) Other Long-Term Liabilities: €606 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:CLARIP Clariane SE CHIX:CLARIP
60 GF Score
Price €4.06
GF Value €2.53
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Clariane SE Other Long-Term Liabilities?

Clariane SE CHIX:CLARIP 60 Other Long-Term Liabilities is €606 Mil as of Jun. 2026. GuruFocus rates CHIX:CLARIP with a GF Score™ of 60/100 and a GF Value™ of €2.53 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Clariane SE's other long-term liabilities for the quarter that ended in Jun. 2026 was €606 Mil.

Clariane SE's quarterly other long-term liabilities declined from Jun. 2025 (€621 Mil) to Dec. 2025 (€603 Mil) but then increased from Dec. 2025 (€603 Mil) to Jun. 2026 (€606 Mil).

Clariane SE's annual other long-term liabilities declined from Dec. 2023 (€675 Mil) to Dec. 2024 (€664 Mil) and declined from Dec. 2024 (€664 Mil) to Dec. 2025 (€603 Mil).

Clariane SE Other Long-Term Liabilities Related Terms

Clariane SE Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Clariane SE's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clariane SE Other Long-Term Liabilities Chart

Clariane SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 807.45 724.15 674.88 664.35 603.23

Clariane SE Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 683.42 664.35 621.34 603.23 606.38
CHIX:CLARIP
60GF Score
Clariane SE CHIX:CLARIP
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clariane SE Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €606 Mil mean?
Clariane SE (CHIX:CLARIP) has a Other Long-Term Liabilities of €606 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Clariane SE and its competitors.
Is Clariane SE's Other Long-Term Liabilities too high?
Clariane SE's current Other Long-Term Liabilities is €606 Mil. Overall, Clariane SE has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's Other Long-Term Liabilities compare to HCA and THC?
Clariane SE's Other Long-Term Liabilities of €606 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Healthcare Providers & Services company?
A good Other Long-Term Liabilities depends on the Healthcare Providers & Services industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Clariane SE and its competitors. Clariane SE's current Other Long-Term Liabilities is €606 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (CHIX:CLARIP) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.53, compared to a current price of €4.06 — trading 60.5% above its estimated fair value. The current Other Long-Term Liabilities is €606 Mil. Clariane SE's overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Clariane SE (CHIX:CLARIP), the current Other Long-Term Liabilities is €606 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clariane SE (CHIX:CLARIP) Overvalued in 2026?

Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued. The current stock price of €4.06 is trading 60.5% above its estimated GF Value™ of €2.53. GuruFocus considers Clariane SE to be Significantly Overvalued.

Key valuation signals for CHIX:CLARIP:

  • Other Long-Term Liabilities: €606 Mil
  • GF Value™: €2.53 vs. price of €4.06 (60.5% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the CHIX:CLARIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clariane SE Business Description

Address 21-25, Rue Balzac, Paris, FRA, 75008
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
60GF Score

Get the complete analysis for CHIX:CLARIP

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.06
Price
€2.53
GF Value